statistiche ricercatore

Continente	#
NA - Nord America	1.130
AS - Asia	562
EU - Europa	461
SA - Sud America	82
AF - Africa	23
Continente sconosciuto - Info sul continente non disponibili	12
OC - Oceania	2
Totale	2.272

Nazione	#
US - Stati Uniti d'America	1.078
SG - Singapore	200
CN - Cina	111
GB - Regno Unito	82
IT - Italia	80
FI - Finlandia	66
HK - Hong Kong	66
SE - Svezia	64
BR - Brasile	62
DE - Germania	57
VN - Vietnam	55
BD - Bangladesh	47
RU - Federazione Russa	33
FR - Francia	28
CA - Canada	25
IN - India	13
KR - Corea	11
MX - Messico	11
ID - Indonesia	9
PL - Polonia	8
JP - Giappone	7
ZA - Sudafrica	7
AR - Argentina	6
BG - Bulgaria	6
MA - Marocco	6
MY - Malesia	6
NL - Olanda	6
SI - Slovenia	6
TR - Turchia	6
AT - Austria	5
IQ - Iraq	5
PK - Pakistan	5
UZ - Uzbekistan	5
UA - Ucraina	4
VE - Venezuela	4
CO - Colombia	3
CR - Costa Rica	3
ES - Italia	3
LT - Lituania	3
PH - Filippine	3
AE - Emirati Arabi Uniti	2
BE - Belgio	2
CL - Cile	2
CW - ???statistics.table.value.countryCode.CW???	2
DZ - Algeria	2
EC - Ecuador	2
IL - Israele	2
IR - Iran	2
JM - Giamaica	2
KE - Kenya	2
NI - Nicaragua	2
NP - Nepal	2
NZ - Nuova Zelanda	2
PA - Panama	2
PY - Paraguay	2
RS - Serbia	2
SC - Seychelles	2
TT - Trinidad e Tobago	2
AD - Andorra	1
AG - Antigua e Barbuda	1
BF - Burkina Faso	1
CZ - Repubblica Ceca	1
DO - Repubblica Dominicana	1
EE - Estonia	1
ET - Etiopia	1
GP - Guadalupe	1
GT - Guatemala	1
IE - Irlanda	1
JO - Giordania	1
LA - Repubblica Popolare Democratica del Laos	1
PE - Perù	1
PT - Portogallo	1
QA - Qatar	1
RO - Romania	1
SA - Arabia Saudita	1
SV - El Salvador	1
TN - Tunisia	1
TW - Taiwan	1
ZM - Zambia	1
Totale	2.262

Nome	#
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study	360
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison	301
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART	293
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients	248
Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: The Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) study	232
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort	214
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART	212
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy	208
Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe	204
Totale	2.272

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	89	0	0	0	0	5	2	3	7	18	4	24	26
2022/2023	241	38	34	23	15	34	17	7	26	14	0	11	22
2023/2024	128	4	10	12	15	29	10	13	17	1	3	5	9
2024/2025	467	14	7	4	42	75	69	44	22	63	18	36	73
2025/2026	888	63	36	46	98	155	68	124	34	67	79	37	81
2026/2027	208	15	42	37	98	16	0	0	0	0	0	0	0
Totale													2.272